Groningen

• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended recruitment
  2023-506842-22-00 7 2025-05-19 Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
• A Double-Blind, Randomized, Placebo-Controlled, Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascendin … Ended recruitment
  2024-519899-72-00 3 2025-05-08 Alzheimer's Disease
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration- … Ended recruitment
  2024-513968-25-00 5 2025-04-28 Metastatic castration-resistant prostate cancer (mCRPC)
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended recruitment
  2024-516609-22-00 5 2025-04-15 Primary Sjögren’s Disease
• BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part … Ended recruitment
  2024-515740-23-00 5 2025-03-25 Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
• HOVON 172 MF: Study on tasquinimod treatment in patients with myelofibrosis Ended recruitment
  2024-511565-11-00 9 2025-02-12 Myelofibrosis
• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended recruitment
  2024-518343-38-00 5 2025-02-12 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn … Ended recruitment
  2023-505394-32-00 5 2025-02-06 chronic graft versus host disease
• POEM Study Ended recruitment
  2024-519386-21-01 5 2025-01-29 Gestational diabetes mellitus
• The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with … Ended recruitment
  2024-511616-24-00 1 2024-12-06 Relapsed and/or Refractory B-cell Lymphoma
• Prevention of the return of nephrotic syndrom in children by adding levamisole to prednisolone treatment Ended recruitment
  2024-517467-23-00 5 2024-11-29 steroid sensitive idiopathic nephrotic syndrome
• HAMLETT. Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A study comparing continuation versus discontinuatio … Ended recruitment
  2024-518769-80-00 6 2024-11-25 HAMLETT compares regular treatment guidelines for patients in remissio
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph … Ended recruitment
  2023-505989-29-00 5 2024-11-21 Extensive stage small cell lung cancer (ES-SCLC)
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu … Ended recruitment
  2023-508077-85-00 5 2024-11-19 Polymyalgia Rheumatica
• A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis. Ended recruitment
  2023-510525-15-00 4 2024-11-18 active antineutrophilic cytoplasmic antibody (ANCA) associated vasculi
• A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended recruitment
  2024-516511-24-00 11 2024-11-14 Chronic myeloid leukaemia
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• Long-term Follow-up Study of Male Adults with Hemophilia B Previously Treated with Etranacogene Dezaparvovec (CSL222) Ended recruitment
  2023-503765-37-00 10 2024-09-30 Hemophilia B
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• A research study to look at long-term treatment with a medicine called NNC6019-0001 for people who have heart failure due to transthyretin a … Ended recruitment
  2022-502605-15-00 4 2024-09-16 Participants with transthyretin amyloid cardiomyopathy (ATTR CM)
• First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in … Ended recruitment
  2022-502808-72-00 4 2024-09-11 Chronic Lymphocytic Leukemia
• Safe Stop ipi-nivo Ended recruitment
  2024-516938-34-00 5 2024-09-11 Melanoma
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)

Showing 337–360 of 679 trials